Know Labs, Inc. has developed a sensor technology that can identify changes in pH levels in real time. The technology, known as Radio Frequency Dielectric Spectroscopy (RFDS), has potential applications in healthcare, food quality, and safety, among other fields. The company has completed extensive research on the technology and has submitted this research for peer review. The research is currently available for review on the company's website.

In the after-market session on Friday, several health care stocks saw movement. Biodesix (BDSX) shares rose by 11.9% to $0.75, with a market cap of $108.8 million. Know Labs (KNW) shares increased by 10.96% to $0.81, and its market value stands at $2.2 million. Gelteq (GELS) shares grew by 10% to $1.1, with a market value of $10.3 million. bluebird bio (BLUE) stock increased by 9.8% to $4.48, with a market cap of $43.6 million. The company also recently released its Q4 earnings. Molecular Partners (MOLN) shares also saw movement.

Verselabs has launched verseOS, a Web3-native operating system intended to streamline the Web3 experience. This operating system is aimed at tackling the complexity and fragmentation currently hampering the widespread adoption of Web3 technologies. It offers a unified ecosystem, easy onboarding, and integration that is user-friendly for developers.

The company released a statement on February 28, 2025, announcing the lifting of the trading suspension on its common stock on the NYSE American effective from March 5, 2025. This is detailed in a Current Report on Form 8-K. However, the information in this report, including Exhibit 99.1, should not be considered filed for the purposes of Section 18 of the Securities Exchange Act of 1934 or included in any filing under the Securities Act of 1933, unless expressly mentioned in such filings.

1) Brief Summary: The company is in a dire financial situation with negative ROE, zero sales growth, and a significant decrease in performance over the past month, quarter and year. The volume of trading is higher than average, indicating a potential sell-off. The company has more liabilities than assets, resulting in negative equity. There's also a net cash outflow, which further indicates financial instability. 2) MARKET_SCORE: 8

: Given the bleak financial status, there's only an 8% chance of an upward movement in the share price. 3) PRICE_TARGET: $0.65

: Given the current trend and financial health, I expect the share price to continue to decline. Thus, the price target is set below the current price at $0.65. 4) AI_RPT_HEADLINE: "Financial Turmoil Ahead: Company's Dire Performance Indicates Potential Downfall"

-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes

====================================================== : 2025-03-31 05:09:57

# Analysis Completed Elapsed Time: 31.30 seconds